Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK Breathes New Life Into Asthma Treatment With Depemokimab
11:19am, Wednesday, 22'nd May 2024
GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma. Depemokimab demonstrated a significant reducti
GSK: Zantac settlement could reach $2bn, says investment bank
07:36am, Tuesday, 21'st May 2024
GSK PLC (LSE:GSK, NYSE:GSK) may face a settlement of up to $2 billion to resolve thousands of lawsuits related to Zantac, a heartburn medication linked to cancer, according to an estimate from the inv
GSK says late-stage trials of potential blockbuster asthma drug met their goals
03:10am, Tuesday, 21'st May 2024
GSK on Tuesday said two late-stage trials of an asthma drug that could have peak sales of more than £3 billion ($3.8 billion) met their goals.
GSK's asthma drug shows promise in reducing severe attacks
02:29am, Tuesday, 21'st May 2024
GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday.
GSK faces whistleblower lawsuit over Zantac cancer risk
04:27pm, Monday, 20'th May 2024
GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn
GSK confirms exit of Haleon stake for £3.9 billion
03:18am, Friday, 17'th May 2024
GSK PLC (LSE:GSK, NYSE:GSK) confirmed it has raised a total of £3.9 billion through the exit of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), the healthcare firm which was spun out by the pharma giant
GSK raises $1.5 bln from offloading Haleon stake at a discount
02:22am, Friday, 17'th May 2024
GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
GSK intends to sell its remaining stake in Haleon
12:33pm, Thursday, 16'th May 2024
British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
Here's Why GSK (GSK) is a Strong Value Stock
10:46am, Wednesday, 08'th May 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
01:00am, Tuesday, 07'th May 2024
BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for seri
Apple, Glencore, Sony, Novo Nordisk, Shell, Goldman Sach, GSK, Qualcomm, AMD, Starbucks, Amazon – Markets Defused
06:01am, Saturday, 04'th May 2024
Markets Defused aims to present an easy-to-understand and straightforward recap of the week's most engaging stock market news Apple impressed Wall Street, Cook promises AI growth Sony stepped in wi
GSK plc (GSK) Q1 2024 Earnings Call Transcript
12:00am, Saturday, 04'th May 2024
GSK plc (NYSE:GSK ) Q1 2024 Earnings Conference Call May 1, 2024 3:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Luke Miels - Chief Comm
Why GSK (GSK) is a Top Growth Stock for the Long-Term
10:46am, Friday, 03'rd May 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
03:01pm, Thursday, 02'nd May 2024
U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Inge
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
01:26pm, Wednesday, 01'st May 2024
Sleeper stocks to buy – based on Nasdaq.com's glossary – represent securities that offer significant price appreciation potential once its fundamentals have been recognized. That could cover a lot
